Life Biosciences plans to begin human clinical trials of a cellular rejuvenation therapy in optic neuropathies after receiving FDA clearance of an investigational new drug application, according to a press release.
ER-100 aims to modify the epigenome of cells to restore injured cells without changing their underlying DNA sequence, according to the release.
“For eye care providers, ER-100 represents a fundamentally new approach to treating optic neuropathies as it targets retinal ganglion cell health rather than focusing on downstream factors such as intraocular pressure,” Sharon